Your browser doesn't support javascript.
loading
Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection.
Ssali, Ivan; Mugaba, Susan; Watelo, Arthur Kalyebi; Bemanzi, Juliana; Katende, Joseph Ssebwana; Oluka, Gerald Kevin; Ankunda, Violet; Baine, Claire; Kato, Laban; Onyachi, Nathan; Muwanga, Moses; Jjuuko, Mark; Kayiwa, John; Nsereko, Christopher; Auma, Betty Oliver; Weiskopf, Daniela; Sette, Alessandro; Lutalo, Tom; Musenero, Monica; Kaleebu, Pontiano; Serwanga, Jennifer.
Afiliação
  • Ssali I; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
  • Mugaba S; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
  • Watelo AK; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
  • Bemanzi J; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
  • Katende JS; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
  • Oluka GK; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
  • Ankunda V; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
  • Baine C; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
  • Kato L; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
  • Onyachi N; Department of Internal Medicine, Masaka Regional Referral Hospital, Masaka, Uganda.
  • Muwanga M; Department of Internal Medicine, Entebbe Regional Referral Hospital, Entebbe, Uganda.
  • Jjuuko M; Department of Internal Medicine, Masaka Regional Referral Hospital, Masaka, Uganda.
  • Kayiwa J; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
  • Nsereko C; Department of Internal Medicine, Entebbe Regional Referral Hospital, Entebbe, Uganda.
  • Auma BO; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
  • Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, USA.
  • Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, USA.
  • Lutalo T; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
  • Musenero M; Science, Technology, and Innovation Secretariat, Office of the President, Government of Uganda, Kampala, Uganda.
  • Kaleebu P; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
  • Serwanga J; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda. Electronic address: Jen
Int J Infect Dis ; 136: 49-56, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37683720
ABSTRACT

OBJECTIVES:

Understanding the immune response in very mild and asymptomatic COVID-19 is crucial for developing effective vaccines and immunotherapies, yet remains poorly characterized. This longitudinal study examined the evolution of interferon (IFN)-γ responses to SARS-CoV-2 peptides in 109 asymptomatic or mildly symptomatic Ugandan COVID-19 patients across 365 days and explored their association with antibody generation.

METHODS:

T-cell responses to spike-containing clusters of differentiation (CD4)-S and CD8 nCoV-A (CD8-A) megapools, and the non-spike CD4-R and CD8 nCoV-B (CD8-B) megapools, were assessed and correlated with demographic and temporal variables.

RESULTS:

SARS-CoV-2-specific IFN-γ responses were consistently detected in all peptide pools and time points, with the spike-targeted response exhibiting higher potency and durability than the non-spike responses. Throughout the entire 365-day infection timeline, a robust positive correlation was observed between CD4 T-cell responses to the spike-derived peptides and anti-spike immunoglobulin G antibody levels, underscoring their interdependent dynamics in the immune response against SARS-CoV-2; in contrast, CD8 T-cell responses exhibited no such correlation, highlighting their distinctive, autonomous role in defense. No meaningful variations in complete blood count parameters were observed between individuals with COVID-19 infection and those without, indicating clinical insignificance.

CONCLUSIONS:

This study highlights the dominant role of spike-directed T-cell responses in mild and asymptomatic disease and provides crucial longitudinal data from Sub-Saharan African settings. The findings provide valuable insights into the dynamics of T-cell responses and their potential significance in developing effective strategies for combating COVID-19.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Uganda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Uganda